Search Results

Theranexus and its partners Beyond Batten Disease Foundation and Cardiff University, announced several presentations at WORLDSymposium 2023, an international scientific event focused on lysosomal diseases.

Theranexus and the Beyond Batten Disease Foundation, have announced the initial results of their Phase I/II clinical trial for juvenile Batten disease.

Theranexus and the Beyond Batten Disease Foundation, have announced receipt of approval from the Food and Drug Administration for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics held in mid-April.

Theranexus and the Beyond Batten Disease Foundation, have announced receipt of approval from the Food and Drug Administration for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics held in mid-April.

Theranexus announces today that it has recruited the last patient in its Phase II trial, entitled “Tolerance and Efficacy of THN102 on Sleepiness in Narcoleptic Patients”.

Orphan Drug Designation (ODD) is a status that provides seven years of additional post-approval protection and exemption from filing fees Rare Pediatric Disease Designation (RPDD) qualifies the sponsor at the time of registration for a salable, transferable priority review voucher which can be used to speed up the approval process for another drug candidate

CASH POSITION AT JUNE 30, 2018: €14.9 million

Preparation of a Phase II program for THN101 in patients with neuropathic pain